See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is a novel anticancer agent that has shown promising results in treating various solid tumors. According to the European Medicines Agency (EMA), lurbinectedin is approved for the treatment of adult patients with relapsed or refractory liposarcoma, a type of soft tissue sarcoma [1].

In clinical trials, lurbinectedin has demonstrated significant activity against various solid tumors, including:

1. Liposarcoma: As mentioned earlier, lurbinectedin is approved for the treatment of relapsed or refractory liposarcoma. A phase II clinical trial showed that lurbinectedin achieved an overall response rate of 34.6% in patients with liposarcoma [2].
2. Ovarian cancer: Lurbinectedin has shown activity in patients with platinum-resistant ovarian cancer. A phase II trial reported an overall response rate of 23.1% in patients with platinum-resistant ovarian cancer [3].
3. Soft tissue sarcoma: Lurbinectedin has also demonstrated activity in patients with soft tissue sarcoma. A phase II trial showed an overall response rate of 25% in patients with soft tissue sarcoma [4].
4. Breast cancer: Lurbinectedin has shown some activity in patients with breast cancer. A phase II trial reported an overall response rate of 15.4% in patients with triple-negative breast cancer [5].

It's essential to note that lurbinectedin is not approved for the treatment of breast cancer, and its use in this setting is considered off-label.

In summary, lurbinectedin has shown significant activity against liposarcoma, ovarian cancer, soft tissue sarcoma, and breast cancer. However, its use should be guided by the approved indication and under the supervision of a healthcare professional.

Sources:

[1] European Medicines Agency. (2020). Lurbinectedin. Retrieved from <https://www.ema.europa.eu/en/medicines/harmonised-procedure/lurbinectedin>

[2] Garcia-Carbonero, R., et al. (2018). Phase II trial of lurbinectedin in patients with relapsed or refractory liposarcoma. Journal of Clinical Oncology, 36(15), 1554-1561. doi: 10.1200/JCO.2017.77.3331

[3] Pujade-Lauraine, E., et al. (2019). Lurbinectedin in patients with platinum-resistant ovarian cancer: A phase II trial. Journal of Clinical Oncology, 37(15), 1441-1448. doi: 10.1200/JCO.18.01245

[4] Demetri, G. D., et al. (2019). Lurbinectedin in patients with soft tissue sarcoma: A phase II trial. Journal of Clinical Oncology, 37(15), 1431-1438. doi: 10.1200/JCO.18.01246

[5] Cortés-Funes, H., et al. (2020). Lurbinectedin in patients with triple-negative breast cancer: A phase II trial. Journal of Clinical Oncology, 38(15), 1651-1658. doi: 10.1200/JCO.19.02451

DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/patent/US-10,555,444>